Fuji Photo Film Company, Limited

Dana-farber-cancer Institute Inc.

Tadao Shishido

Hiroyuki Mifune

Shoji Ishiguro

Keiichi Adachi

Yoshiaki Suzuki

Keisuke Shiba

Lan Bo Chen

Reiichi Ohi

Yoshio Inagaki

Toshiaki Aono

Takeshi Hirose

Seiiti Kubodera

Masanao Hinata

Yoshiharu Fuseya

Hiroshi Hara

Shigeo Hirano

Masaki Okazaki

Yuji Mihara

Harumi Katsuyama

Takao Masuda

Atsuaki Arai

Nobuyoshi Sekikawa

Tatsuo Nishimura

Tadao Sakai

Masayoshi Kawai

Teruaki Tsujikawa

Akira Ogawa

Akira Sato

Minoru Yamada

Katsumi Hayashi

Shunji Takada

Shinpei Ikenoue

Shinji Ueda

Hirotomo Sasaki

Isamu Itoh

Akio Miyake

Toshinao Ukai

Akio Mitsui

Akihiko Ikegawa

Nobuo Sakai

Akira Umehara

Junya Nakajima

Noboru Sasaki

Isao Shimamura

Sadanobu Shuto

Takashi Toyoda

Haruhiko Iwano

Keizo Koya

Masayuki Kawakami

Yasuhiro Noguchi

Jun Hayashi

Akio Okumura

Yoshitaka Akimura

Takeo Sakai

Kenji Sashihara

Shuzo Suga

Naoki Arai

Motohiko Tsubota

Seiki Sakanoue

Nobuyuki Tsujino

Tohru Sueyoshi

Yasuo Kasama

Syunichi Kondoh

Akikazu Mikawa

Yukihide Urata

Takeshi Takayama

Yoshiro Kawashima

Yoo Iijima

Masaaki Torigoe

Joji Nagaoka

Minoru Matsuki

Jisaburo Ueyanagi

Nobuo Furtachi

A pharmaceutical composition for treatment of cancer in a mammal comprising:

Composition and method for treating cancer

An anti-cancer composition comprising a rhodacyanine compound and cyclodextrin or derivative thereof, wherein said rhodacyanine compound is selected from the group consisting of compounds represented by the following Formula (I), the cation moiety of which has a log P value of 4.5-12: ##STR1## wherein X.sub.1 and X.sub.2, which may be the same or different, each represents O, S, Se, ##STR2## Y.sub.1 represents O, S, Se, or ##STR3## R.sub.1 and R.sub.3, which may be the same or different, each represents an alkyl group; R.sub.2 represents an alkyl group, an aryl group or a heterocyclic group; Z.sub.1 and Z.sub.2, which may be the same or different, each represents an atomic group necessary to form a 5- or 6-membered ring; L.sub.1, L.sub.2 and L.sub.3, which may be the same or different, each represents a methine group or nitrogen atom and L.sub.1 and R.sub.3 may combine and form a 5- or 6-membered ring; R.sub.4 and R.sub.5, which may be the same or different, each represents an alkyl group; R.sub.6 and R.sub.7, which may be the same or different, each represents an alkyl group or an aryl group; Q represents a pharmaceutically acceptable anion; j and k, which may be the same or different, each represents 1 or 2; m and n, which may be the same or different, each represents 0 or 1.

Anti-cancer composition comprising rhodacyanine compound and cyclodextrin

A pharmaceutical composition for treatment of cancer in an animal comprising: (A) a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by the General Formula (I). ##STR1## wherein Z.sub.1 and Z.sub.2, which may be the same or different, each represents an atomic group necessary to form a 5- or 6-membered ring; R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, each represents an alkyl group or an aryl group; L.sub.1 and L.sub.2 each represents a methine group or a substituted methine group; X represents a pharmaceutically acceptable anion; k represents a number necessary for electrical charge balance; n represents 0 or 1; and (B) a pharmaceutically acceptable carrier or diluent.

A pharmaceutical composition for treatment of cancer comprises:

A nonlinear optical material comprising a compound represented by formula (I) ##STR1## wherein Z.sup.1, Z.sup.2, R.sup.1, X and n are as defined before, or a compound represented by formula (II) ##STR2## wherein Z.sup.11 and Z.sup.12 are as defined before. The compounds of formulae (I) and (II) exhibits high transmittance to blue light and high nonlinear optical effects.

Nonlinear optical material

A silver halide photographic emulsion is subjected to sulfur or gold-sulfur sensitization in the presence of a combination of (1) at least one of an organic thioether compound or a tetrasubstituted thiourea and (2) a nitrogen-containing heterocyclic compound, to achieve the prevention of pressure desensitization and safelight aptitude deterioration.

Method for producing silver halide photographic emulsion and silver

A nonlinear optical material comprising a compound represented by formula (I) ##STR1## wherein Z.sup.1, Z.sup.2, R.sup.1, X and n are as defined before, or a compound represented by formula (II) ##STR2## wherein Z.sup.11 and Z.sup.12 are as defined before. The compounds of formula (I) and (II) exhibits high transmittance to blue light and high nonlinear optical effects.

A silver halide photographic material comprising silver halide emulsion including a telluroether compound of the formula (I):

Silver halide photographic materials

A process for forming a superhigh contrast negative image with a stable developer is disclosed, which comprises development processing a silver halide photographic material in the presence of a compound of formula (I) and a compound of formula (II) as defined in the specification.

Process for forming a superhigh contrast negative image

Novel compounds are disclosed which are 4-amino-2,3-di-substituted-1-(mono- or trichlorophenyl)-3-pyrazolin-5-ones-representing by the following formulae (1) to (3); ##STR1## and acid addition salts thereof. The compounds can be easily produced and are useful for qualitative analysis or quantitative analysis of hydrogen peroxide when used as a component of a color indicator composition for detecting hydrogen peroxide.

4-amino-2,3-di-substituted-1-(mono- or

A process for preparing a silver halide emulsion using a sulfur-containing inhibitor which substantially inhibits growth of silver halide grains is disclosed. The sulfur-containing inhibitor is inactivated by addition of an oxidizing agent capable of reducing or eliminating the inhibitory activity of the sulfur-containing inhibitor. By the process, adverse influences of the sulfur-containing inhibitor upon chemical ripening or development can be excluded.

Process for preparing silver halide emulsion and photographic

A process for processing a silver halide color reversal photographic light-sensitive material is disclosed, which comprises developing an imagewise exposed silver halide color reversal photographic light-sensitive material with a black-and-white developer containing at least one compound selected from the compounds of Group A, at least one compound selected from the compounds of Group B, and preferably further at least one compound selected from the compounds of Group C, wherein

Process for processing a color reversal photographic light-sensitive

Process for preparing silver halide emulsion utilizing a

Compounds are disclosed which are 4-amino-2,3-di-substituted-1-(mono- or trichlorophenyl)-3-pyrazolin-5-ones represented by the following formulae (1) to (3): ##STR1## and acid addition salts thereof. The compounds can be easily produced and are useful for qualitative analysis or quantitative analysis of hydrogen peroxide when used as a component of a color indicator composition for detecting hydrogen peroxide.

4-amino-2-methyl-3-phenyl-1-(2,4,6-trichlorophenyl)-3-pyrazolin-5-one

A silver halide emulsion and a process for producing the same are disclosed. In the process, at least one compound selected from hydrogen peroxide or an adduct or precursor thereof, a peroxy acid salt, and ozone is added to an emulsion in the step prior to the end of chemical ripening. The emulsion exhibits reduced fog, improved stability with time, and improved sensitivity.

Silver halide photographic emulsion and process for production thereof

Growing community of inventors

Minami-ashigara, Japan

Tadao Shishido